TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05633199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
Study: NCT05689268

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EUS-PPG and HVPG
Description: EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed.
Study: NCT05823181

Intervention type: DEVICE
Intervention: laparoscopy
Description: laparoscopic exploration of common bile duct

Intervention type: DEVICE
Intervention: laparoscopy
Description: laparoscopic exploration of common bile duct
Study: NCT06187480

Intervention type: PROCEDURE
Intervention: total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)
Description: The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.

Intervention type: PROCEDURE
Intervention: total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)
Description: The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
Study: NCT05703204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF32101
Description: The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
Study: NCT05493124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manpixiao
Description: A traditional Chinese medicine composition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Other drugs that may have therapeutic effects
Study: NCT05359224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel group
Description: Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given prasugrel 5mg once. And aspirin 100mg and prasugrel 5mg will be maintained for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel group
Description: Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given pletaal 100mg once. And aspirin 100mg and clopidogrel 75mg mg will be maintained for 30 days.
Study: NCT05844748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetes education with motivational interview technique
Description: Techniques such as developing empathy, developing disengagement, turning with resistance, supporting self-efficacy, avoiding advice, a simple decision, importance-trust scale, open-ended questions, reflection and segmentation in motivational interviews.
Study: NCT04975620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fine needle biopsy
Description: Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fine needle biopsy
Description: Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet
Study: NCT04636996

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: artificial intelligence assisted follow-up
Description: We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: artificial intelligence assisted follow-up
Description: We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
Study: NCT05890209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring device
Description: A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
Study: NCT06397092

Intervention type: PROCEDURE
Intervention: transapical beating-heart septal myectomy
Description: The patients with hypertrophic cardiomyopathy undergoing TA-BSM
Study: NCT06363292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-231
Description: Moxifloxacin 0.5% Ophthalmic solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIGAMOXI®
Description: Moxifloxacin 0.5% Ophthalmic solution.
Study: NCT04969575

Intervention type: OTHER
Intervention: Insemination and culture
Description: All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.

Intervention type: OTHER
Intervention: Insemination and culture
Description: All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.

Intervention type: OTHER
Intervention: Media refreshment Group 1
Description: Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3).

Intervention type: OTHER
Intervention: Culture media preparation and refreshment
Description: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator.
Study: NCT05839925

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II
Description: The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II
Description: The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
Study: NCT04969575

Intervention type: OTHER
Intervention: Culture media preparation and refreshment
Description: 30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator.

Intervention type: OTHER
Intervention: Embryo grading
Description: Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.

Intervention type: OTHER
Intervention: Embryo grading
Description: Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.

Intervention type: OTHER
Intervention: Media refreshment Group 2
Description: Zygote scoring on day 1 (18-20hpi). Culture media refreshment will be done 114-118 hours post insemination (Day5).
Study: NCT06317727

Intervention type: DEVICE
Intervention: Irreversible Electroporation using EndoVE(Endoscopic Vacuum Electrode) and electrical pulses generated using ePORE(electroporation device)
Description: The use of pulsed field ablation via irreversible electroporation delivered during flexible lower gastrointestinal endoscopy
Study: NCT06088875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulization
Description: Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spray-as-you-go
Description: Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
Study: NCT05749965

Intervention type: PROCEDURE
Intervention: Unicompartmental knee arthroplasty
Description: medial unicompartmental knee arthroplasty

Intervention type: PROCEDURE
Intervention: Unicompartmental knee arthroplasty
Description: medial unicompartmental knee arthroplasty
Study: NCT05158140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Single IM dose of 50 μg/0.25 mL mRNA-1273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Single IM dose of 50 μg/0.25 mL mRNA-1273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Single IM dose of 50 μg/0.25 mL mRNA-1273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Single IM dose of 50 μg/0.25 mL mRNA-1273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for V110
Description: Single IM dose of 0.5 mL placebo for V110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for V110
Description: Single IM dose of 0.5 mL placebo for V110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for V114
Description: Single IM dose of 0.5 mL placebo for V114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for V114
Description: Single IM dose of 0.5 mL placebo for V114
Study: NCT05110131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device for performing biopsy via electromagnetic navigation bronchoscopy
Description: Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device for performing biopsy via electromagnetic navigation bronchoscopy
Description: Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
Study: NCT04380649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New headset prototype
Description: creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
Study: NCT01716676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine CPAP monitoring (webpage and televisit)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP monitoring
Study: NCT05487755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20Mg Oral Tablet
Description: Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 MG Oral Tablet
Description: Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
Study: NCT05338372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two days forest therapy
Description: Participants attend two days (with a break day in between) of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three days forest therapy
Description: Participants attend three days of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
Study: NCT04714281

Intervention type: DEVICE
Group type: OTHER
Intervention: Dialyser
Description: Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
Study: NCT06318039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel program
Description: Applying new training method; the Nordic hamstring exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novel program
Description: Applying new training method; the Nordic hamstring exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional program
Description: Conventional rehabilitation training administered
Study: NCT05595941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele-yoga
Description: Each session will include postural exercises (asanas), standing, sitting and lying down, in order to work on balance, muscular strength and endurance, as well as flexibility. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, cushions, blocks (provided free to each participant). In addition, breathing work will accompany these postures. A relaxing passive meditation is practiced at the end of each session, in a lying posture called Savasana. The complexity of the postures, their holding time, or the number of repetitions will increase as the program progresses, relative to the abilities of each participant.
Study: NCT05252871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating
Description: Subjects will be wearing three different PAL designs with different geometries of the optical progression.
Study: NCT06318039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional program
Description: Conventional rehabilitation training administered
Study: NCT05361486

Intervention type: OTHER
Intervention: Training on revised algorithm
Description: relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly

Intervention type: OTHER
Intervention: Enhancing Pharmacovigilance
Description: Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.

Intervention type: OTHER
Intervention: Supervision of malaria services in selected facilities.
Description: Supervisors in target regions will be trained as for the HCPs.

Intervention type: DIAGNOSTIC_TEST
Intervention: G6PD testing
Description: G6PD test after Malaria Vivax diagnosis

Intervention type: DRUG
Intervention: Tafenoquine
Description: 300 mg (2x150mg tablets) tafenoquine

Intervention type: DRUG
Intervention: Primaquine
Description: 0.5mg/kg/7 days

Intervention type: OTHER
Intervention: Follow Up Visit at Day 3 [+2 days] after treatment start
Description: It will be checked if all patients have a Follow Up Visit at Day 3 \[+2 days\] after treatment start
Study: NCT06607718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Resistance training for elderly patients in the acute care unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Resistance training for elderly patients in the acute care unit.
Study: NCT05252871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating
Description: Subjects will be wearing three different PAL designs with different geometries of the optical progression.
Study: NCT04836624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Co-designing of personalised aids of daily living
Description: In the initial session the researcher will work with the participants to identify challenges in daily living for the device to overcome.~In between sessions the researcher will design and manufacture different solutions which will then be sent out for the participant to trial. The participant will then meet with the researcher to and feedback on the device provided. Feedback from the user is used to alter and improve the design of the device; new device(s) are then , enabling the design to be adapted to the participants needs. The process of design changes and feedback forms an iterative loop. This is expected to continue for 4-5 appointments over a period of serveral months until a final design is agreed upon.~After the device is issue, both qualitative and quantitative outcome measures are provided to participants to complete, including questionnaires and semi-structured interviews. .
Study: NCT06607718

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation
Description: To receive two daily packs of a hypercaloric and hyperproteic oral nutritional supplement for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation
Description: To receive two daily packs of a hypercaloric and hyperproteic oral nutritional supplement for 3 months.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: No intervention
Study: NCT06610474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of the online Talk to Nathan about Prostate Cancer decision aid
Description: This decision aid is publicly available at this website in both English or Spanish: https://www.cdc.gov/prostate-cancer/talk-to-nathan/index.html

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of a standard prostate cancer screening decision aid
Description: The standard decision aid is available here and will be used in either English or Spanish: https://massclearinghouse.ehs.state.ma.us/PROG-CANC/CA1382kit.html

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of standard prostate cancer education materials
Description: The standard education materials are available from the National Cancer Institute (NCI) website in English or Spanish: https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq
Study: NCT06614608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% ASKC200
Description: 5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% ASKC200
Description: 1% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of1% for this study.
Study: NCT06617754

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies

Intervention type: BIOLOGICAL
Intervention: Biologic drugs
Description: Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies